There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Abeona Therapeutics (NASDAQ:ABEO), Aurinia Pharmaceuticals (NASDAQ:AUPH) and Stemline Therapeutics Inc (NASDAQ:STML) with bullish sentiments.
Abeona Therapeutics (ABEO)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Abeona Therapeutics today and set a price target of $30. The company’s shares closed on Friday at $13.65.
“Valuation methodology, risks and uncertainties. We ascribe a total risk-adjusted net present value (rNPV) of $1.46B to Abeona’s technology platforms, which yields a price per share of $30.00 based on about 50M shares outstanding as of end-2Q 2019. We utilize an 85% probability of success for EB-101.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -3.0% and a 35.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abeona Therapeutics with a $29.57 average price target, representing an 116.6% upside. In a report issued on August 10, Maxim Group also maintained a Buy rating on the stock with a $35 price target.
Aurinia Pharmaceuticals (AUPH)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $15. The company’s shares closed on Friday at $5.37.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 20.2% and a 41.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Paratek Pharmaceuticals.
Currently, the analyst consensus on Aurinia Pharmaceuticals is a Moderate Buy with an average price target of $16.50, representing a 207.3% upside. In a report issued on August 10, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $18 price target.
Stemline Therapeutics Inc (STML)
Roth Capital analyst Jotin Marango reiterated a Buy rating on Stemline Therapeutics Inc today and set a price target of $30. The company’s shares closed on Friday at $14.95.
“We expect acceptance of the Elzonris BLA by end-August, and approval of a label in front-line BPDCN by early 1Q19. In parallel to the commercial launch in BPDCN next year, we guide investor attention to the opportunity and progress in lateral indications, such as CMML, which in our view may easily and quickly compound the value of Elzonris. We reiterate our Buy rating and $30 price target. Call us to discuss and CMML.”
According to TipRanks.com, Marango is a 4-star analyst with an average return of 18.5% and a 47.2% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Actinium Pharmaceuticals, and Aptevo Therapeutics Inc.
Currently, the analyst consensus on Stemline Therapeutics Inc is a Strong Buy with an average price target of $34, which is a 127.4% upside from current levels. In a report issued on August 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $38 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.